Immune system plays an important role in the success and failure of conventional cancer therapy

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 125-128

  Gough, Michael J ^a   Crittenden, Marka R ^b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b Oregon Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; GAMMA INTERFERON; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA; T CELL DEPLETION; T LYMPHOCYTE; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; CANCER VACCINES; CELLULAR MICROENVIRONMENT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857595473     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.157     Document Type: Review

References (28)

1. Johnson JI, Decker S, Zaharevitz D et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84(10), 1424-1431 (2001).
2. Shankaran V, Ikeda H, Bruce AT et al. IFNg and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001).
3. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56(20), 4625-4629 (1996).
4. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1(1), 54-67 (2011).
5. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
6. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007).
7. Gough MJ, Crittenden MR, Sarff M et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J. Immunother. 33(8), 798-809 (2010).
8. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96(26), 15074-15079 (1999).
9. 8+T cells: Changing strategies for cancer treatment. Blood 114(3), 589-595 (2009).
10. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2 Pt 1), 728-734 (2005).
11. Moore RJ, Owens DM, Stamp G et al. Mice deficient in tumor necrosis factor?a are resistant to skin carcinogenesis. Nat. Med. 5(7), 828-831 (1999).
12. Lin EY, Li JF, Bricard G et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 1(3), 288-302 (2007).
13. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56(18), 4264-4266 (1996).
14. Curti BD, Urba WJ, Alvord WG et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment. Cancer Res. 53(Suppl. 10), S2204-S2207 (1993).
15. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004).
16. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
17. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315(26), 1650-1659 (1986).
18. Nuyten DS, Kreike B, Hart AA et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 8(5), R62 (2006).
19. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
20. 4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2), 91-102 (2009).
21. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62(5), 1462-1470 (2002).
22. Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69(6), 2685-2693 (2009).
23. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10(3), 294-298 (2004).
24. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204(1), 49-55 (2007).
25. Zhang B, Karrison T, Rowley DA, Schreiber H. IFNσg-and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118(4), 1398-1404 (2008).
26. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68(13), 5206-5215 (2008).
27. Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57(18), 4036-4041 (1997).
28. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17(12), 4101-4109 (2011).